99 related articles for article (PubMed ID: 1581878)
1. Three neuroblastoma cell lines established from consecutive samples of one patient which show distinct morphologic features, MYCN amplification, and surface marker expression.
Kees UR; Ford J; Dawson VM; Ranford PR; Armstrong JA
Cancer Genet Cytogenet; 1992 Apr; 59(2):119-27. PubMed ID: 1581878
[TBL] [Abstract][Full Text] [Related]
2. Detection of MYCN amplification in three neuroblastoma cell lines by non-radioactive chromosomal in situ hybridization.
McRobert TL; Rudduck C; Kees UR; Garson OM
Cancer Genet Cytogenet; 1992 Apr; 59(2):128-34. PubMed ID: 1581879
[TBL] [Abstract][Full Text] [Related]
3. Neuroblastoma cells can actively eliminate supernumerary MYCN gene copies by micronucleus formation--sign of tumour cell revertance?
Ambros IM; Rumpler S; Luegmayr A; Hattinger CM; Strehl S; Kovar H; Gadner H; Ambros PF
Eur J Cancer; 1997 Oct; 33(12):2043-9. PubMed ID: 9516850
[TBL] [Abstract][Full Text] [Related]
4. Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma.
Squire JA; Thorner PS; Weitzman S; Maggi JD; Dirks P; Doyle J; Hale M; Godbout R
Oncogene; 1995 Apr; 10(7):1417-22. PubMed ID: 7731693
[TBL] [Abstract][Full Text] [Related]
5. Analysis of candidate gene co-amplification with MYCN in neuroblastoma.
George RE; Kenyon R; McGuckin AG; Kohl N; Kogner P; Christiansen H; Pearson AD; Lunec J
Eur J Cancer; 1997 Oct; 33(12):2037-42. PubMed ID: 9516849
[TBL] [Abstract][Full Text] [Related]
6. MYCN amplification and 17q in neuroblastoma: evidence for structural association.
O'Neill S; Ekstrom L; Lastowska M; Roberts P; Brodeur GM; Kees UR; Schwab M; Bown N
Genes Chromosomes Cancer; 2001 Jan; 30(1):87-90. PubMed ID: 11107180
[TBL] [Abstract][Full Text] [Related]
7. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
8. Human neuroblastoma cell lines that express N-myc without gene amplification.
Wada RK; Seeger RC; Brodeur GM; Einhorn PA; Rayner SA; Tomayko MM; Reynolds CP
Cancer; 1993 Dec; 72(11):3346-54. PubMed ID: 8242562
[TBL] [Abstract][Full Text] [Related]
9. Expression of a 260 kDa neuroblastoma surface antigen, the target of cytotoxic natural human IgM: correlation to MYCN amplification and effects of retinoic acid.
David K; Ehrhardt A; Ollert MW; Erttmann R; Bredehorst R; Vogel CW
Eur J Cancer; 1997 Oct; 33(12):1937-41. PubMed ID: 9516828
[TBL] [Abstract][Full Text] [Related]
10. MYCN is retained in single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells.
Corvi R; Amler LC; Savelyeva L; Gehring M; Schwab M
Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5523-7. PubMed ID: 8202521
[TBL] [Abstract][Full Text] [Related]
11. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
12. Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes.
Sarkar AK; Nuchtern JG
Cancer Res; 2000 Apr; 60(7):1908-13. PubMed ID: 10766179
[TBL] [Abstract][Full Text] [Related]
13. CD44H expression by human neuroblastoma cells: relation to MYCN amplification and lineage differentiation.
Gross N; Beretta C; Peruisseau G; Jackson D; Simmons D; Beck D
Cancer Res; 1994 Aug; 54(15):4238-42. PubMed ID: 7518353
[TBL] [Abstract][Full Text] [Related]
14. Different effects of TrkA expression in neuroblastoma cell lines with or without MYCN amplification.
Eggert A; Ho R; Ikegaki N; Liu XG; Brodeur GM
Med Pediatr Oncol; 2000 Dec; 35(6):623-7. PubMed ID: 11107132
[TBL] [Abstract][Full Text] [Related]
15. The DDX1 gene maps within 400 kbp 5' to MYCN and is frequently coamplified in human neuroblastoma.
Amler LC; Schürmann J; Schwab M
Genes Chromosomes Cancer; 1996 Feb; 15(2):134-7. PubMed ID: 8834178
[TBL] [Abstract][Full Text] [Related]
16. Detection of MYCN amplification using blood plasma: noninvasive therapy evaluation and prediction of prognosis in neuroblastoma.
Kojima M; Hiyama E; Fukuba I; Yamaoka E; Ueda Y; Onitake Y; Kurihara S; Sueda T
Pediatr Surg Int; 2013 Nov; 29(11):1139-45. PubMed ID: 24022278
[TBL] [Abstract][Full Text] [Related]
17. Cell lineage and differentiation state are primary determinants of MYCN gene expression and malignant potential in human neuroblastoma cells.
Spengler BA; Lazarova DL; Ross RA; Biedler JL
Oncol Res; 1997; 9(9):467-76. PubMed ID: 9495452
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
Marrano P; Irwin MS; Thorner PS
Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
[TBL] [Abstract][Full Text] [Related]
19. Bi-modal differentiation pattern in a new human neuroblastoma cell line in vitro.
Matsushima H; Bogenmann E
Int J Cancer; 1992 May; 51(2):250-8. PubMed ID: 1568793
[TBL] [Abstract][Full Text] [Related]
20. Amplification of a DEAD box gene (DDX1) with the MYCN gene in neuroblastomas as a result of cosegregation of sequences flanking the MYCN locus.
Noguchi T; Akiyama K; Yokoyama M; Kanda N; Matsunaga T; Nishi Y
Genes Chromosomes Cancer; 1996 Feb; 15(2):129-33. PubMed ID: 8834177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
